Dose Finding Study In Subjects With Crow's Feet

Dose Finding Study of Botulinum Neurotoxin Type A In Subjects With Crow's Feet (Lateral Canthal Lines)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01951742

Enrollment

145

Registered

2013-09-27

Start date

2013-09-30

Completion date

2014-01-31

Last updated

2014-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crow's Feet, Lateral Canthal Lines

Keywords

wrinkles

Brief summary

The purpose of this study is to establish the therapeutic range of ANT-1401 in the treatment of Crow's Feet.

Interventions

BIOLOGICALANT-1401

Active

BIOLOGICALVehicle

Vehicle

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* 30 - 60 years of age * mild to moderate Crow's Feet wrinkles at rest * moderate to severe Crow's Feet wrinkles on contraction * willingness to refrain from any product affecting skin remodeling * female subjects must be not pregnant and non-lactating

Exclusion criteria

* history of peri-ocular surgery, brow lift or related procedures * procedures affecting the lateral canthal region in the prior 12 months * application of topical prescription medication to the treatment area * female subjects who are pregnant or are nursing a child

Design outcomes

Primary

Measure	Time frame	Description
Investigators Global Assessment Scale	Week 4	Crow's Feet Wrinkle Scale

Secondary

Measure	Time frame	Description
Subject Self-Assessment score	up to 12 12 weeks	Subjects self assessment of severity of Crow's Feet

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026